-+ 0.00%
-+ 0.00%
-+ 0.00%

UMOJA BIOPHARMA ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR UB-VV400, THE INDUSTRY’S FIRST KNOWN CD22-DIRECTED IN VIVO CAR T CELL THERAPY FOR RELAPSED/REFRACTORY B CELL MALIGNANCIES

路透·07/16/2026 12:00:24

登录查看新闻详情